Last reviewed · How we verify

Universidad de Colima — Portfolio Competitive Intelligence Brief

Universidad de Colima pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Probiotic (Lactobacillus reuteri Prodentis Probiotic (Lactobacillus reuteri Prodentis marketed Probiotic Dentistry / Oral Health
Oral Electrolytes Oral Electrolytes marketed
ketamine sedation versus midazolam sedation ketamine sedation versus midazolam sedation phase 3 Anesthetic NMDA receptor Anesthesiology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. BioBalance Corporation · 1 shared drug class
  2. Biocodex · 1 shared drug class
  3. CD Pharma India Pvt. Ltd. · 1 shared drug class
  4. CHU de Quebec-Universite Laval · 1 shared drug class
  5. Chuncheon Sacred Heart Hospital · 1 shared drug class
  6. Dow University of Health Sciences · 1 shared drug class
  7. Express Specialty Pharmacy · 1 shared drug class
  8. Aga Khan University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidad de Colima:

Cite this brief

Drug Landscape (2026). Universidad de Colima — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-de-colima. Accessed 2026-05-16.

Related